Dow Jones Darling Merck Pops As Cancer 'Star' Drives Quarterly Beat

Published on 25 Apr 2024 on Investor's Business Daily

Merck's bread-and-butter cancer drug grew by double digits again in the first quarter.

Read the rest of the article

Start tracking your investments with Statfolio

D.W. Daniel’s defense held on for so long in the Class AAA high school boys soccer state...

The Greenville News 11 May 2024

Merck has announced that its Phase III KEYNOTE-B21 (ENGOT-en11/GOG-3053) clinical trial of KEYTRU...

Clinical Trials Arena via Yahoo Finance 10 May 2024

By buying an index fund, investors can approximate the average market return. But if you pick the...

Simply Wall St. via Yahoo Finance 10 May 2024

(Reuters) - Merck said on Thursday its treatment for a type of uterus cancer did not meet the mai...

WSAU Wausau 9 May 2024

Among U.S. exchange traded funds, the Nasdaq 100 tracker Invesco QQQ Trust ETF fell 0.3%, as the...

Investor's Business Daily 9 May 2024

Dividends may be boring but are essential to building a well-balanced portfolio. After all, divid...

Motley Fool via Yahoo Finance 9 May 2024

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a goo...

Zacks via Yahoo Finance 9 May 2024

The drugmaker's Keytruda therapy in combination with chemotherapy was being evaluated in about 1,...

Reuters via Yahoo News 9 May 2024

Every pharmaceutical company is constantly searching for its next blockbuster — the billion-dolla...

Quartz 8 May 2024

Among the best stocks to watch, Dow Jones drug giant Merck, Nvidia, Chipotle Mexican Grill and NX...

Investor's Business Daily 6 May 2024